{"entity":{"id":"proda-biotech","kind":"company","name":"ProDa BioTech","aka":["ProDa BioTech, LLC","PRODA BIOTECH, LLC"],"tldr":"ProDa BioTech is a company in Marietta, Georgia, developing ProAgio, a protein drug that kills cells carrying an integrin receptor in tumours and the tissue around them. ProAgio is in an early trial with chemotherapy in triple-negative breast cancer that has spread.","summary":"ProDa BioTech, LLC, of Marietta, Georgia, sponsors the phase 1/2 trial NCT06460298, which the registry describes as evaluating ProAgio, an anti-alpha-v-beta-3 integrin cytotoxin, with gemcitabine in metastatic triple-negative breast cancer. In fiscal year 2026 NCI awarded it USD 1,139,113 under SBIR grant 1R44CA314813-01 to develop a new combination therapy for pancreatic ductal adenocarcinoma; the abstract describes depleting cancer-associated fibroblasts and pancreatic stellate cells, which lay down the dense stroma that limits drug delivery, and altering abnormal tumour vessels.","asOf":"2026-11-04","links":[{"label":"NIH RePORTER: award 1R44CA314813-01","url":"https://reporter.nih.gov/project-details/11409793"},{"label":"ClinicalTrials.gov: trials led by ProDa BioTech","url":"https://clinicaltrials.gov/search?lead=ProDa%20BioTech"}],"tags":[],"related":[],"cancers":["pancreatic","tnbc"],"sections":["targeted-therapy"],"technologies":[],"targets":[],"drugs":["proagio"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06460298"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["No company website was found. The record rests on the NIH RePORTER award and the ClinicalTrials.gov record for NCT06460298, read on 4 November 2026."],"hq":"Marietta, GA","country":"US","companyType":"biotech","stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":1139113,"source":"https://reporter.nih.gov/project-details/11409793","note":"NCI SBIR Phase II (R44) award 1R44CA314813-01: Development of a new combination therapy for pancreatic ductal adenocarcinoma treatment"}]},"route":"/companies/proda-biotech/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"drug":[{"id":"proagio","kind":"drug","name":"ProAgio","route":"/drugs/proagio/"}],"trial":[{"id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","route":"/trials/nct06460298/"}]}}